Is Stevanato (STVN) a Solid Growth Stock? 3 Reasons to Think "Yes"
Stevanato (STVN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Zacks Investment Research8/5/2026Positive
STVN
Stevanato Group SpANYSEHEALTHCAREMEDICAL INSTRUMENTS & SUPPLIES
Key Statistics
Market Cap
$5.81B
P/E Ratio
37.96
EPS
$0.56
Beta
0.74
52W High
$27.90
52W Low
$12.84
50-Day MA
$19.02
200-Day MA
$18.52
Dividend Yield
0.00%
Profit Margin
11.00%
Forward P/E
6.79
PEG Ratio
0.36
About Stevanato Group SpA
Stevanato Group SpA (STVN) is a leading global provider of advanced drug delivery systems, specializing in innovative glass and polymer packaging solutions designed for injectable medications used by the pharmaceutical and biotechnology industries. With a steadfast focus on quality, sustainability, and the adoption of cutting-edge technologies, Stevanato is well-positioned to benefit from the burgeoning demand within the biopharmaceutical sector. The company’s dedication to enhancing the efficiency and reliability of drug administration makes it an attractive proposition for institutional investors looking for opportunities in healthcare innovation and sustainable growth.
Fundamentals
| Revenue (TTM) | $1.23B |
| Gross Profit (TTM) | $360.21M |
| EBITDA | $298.83M |
| Operating Margin | 17.20% |
| Return on Equity | 9.13% |
| Return on Assets | 5.45% |
| Revenue/Share (TTM) | $4.49 |
| Book Value | $6.56 |
| Price-to-Book | 3.22 |
| Price-to-Sales (TTM) | 4.74 |
| EV/Revenue | 4.364 |
| EV/EBITDA | 18.23 |
| Quarterly Earnings Growth (YoY) | -26.50% |
| Quarterly Revenue Growth (YoY) | 7.80% |
| Shares Outstanding | $49.83M |
| Float | $49.03M |
| % Insiders | 1.64% |
| % Institutions | 97.14% |
Historical Volatility
HV 10-Day
34.41%
HV 20-Day
29.26%
HV 30-Day
37.37%
HV 60-Day
38.08%
HV Rank
11.5%
Volatility is currently contracting
Analyst Ratings
Consensus ($24.74 target)
2
Strong Buy7
Buy2
HoldLatest News
Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcript
Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcript
Seeking Alpha8/4/2026Neutral
Stevanato Group (STVN) Q2 Earnings Top Estimates
Stevanato Group (STVN) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.12 per share a year ago.
Zacks Investment Research8/4/2026Positive
Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2026. Second Quarter of 2026 Highlights (comparisons to prior-year period) Revenue increased 8% to €302.0 million, with high-value solutions representing 45% of total revenue. Gross profit margin increase.
Business Wire8/4/2026Neutral
Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology and life sciences industries, today announced that liraglutide-based combination products incorporating Stevanato Group's proprietary Alina® pen injector platform have received marketing authorizations in Europe. The authorizations relate to finished combination products held by the respective Mark.
Business Wire7/30/2026Neutral
Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the second quarter of 2026 on Tuesday, August 4, 2026, at 6:30 a.m. (EDT). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (EDT) on Tuesday, August 4, 2026, to discu.
Business Wire7/21/2026Neutral
Stevanato: HVS Momentum Overshadows Engineering Weakness, Offering Compelling Upside
Stevanato Group is reiterated as a Buy, driven by robust Q1 results and a compelling long-term growth trajectory. The High-Value Solutions segment accelerated, now comprising 47% of sales, fueled by broad biologics and injectable therapies demand. Management attributed the slowdown in the Engineering segment to project timing and order delays rather than competitive pressure or deteriorating demand. Importantly, segment profitability improved despite lower volumes.
Seeking Alpha6/11/2026Positive
Implied Volatility Surging for Stevanato Stock Options
Investors need to pay close attention to STVN stock based on the movements in the options market lately.
Zacks Investment Research6/3/2026Neutral
Stevanato Group S.p.A. (STVN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Stevanato Group S.p.A. (STVN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha5/12/2026Neutral
Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2026. First Quarter of 2026 Highlights (comparisons to prior-year period) For the first quarter of 2026, revenue increased 7% (10% on a constant currency basis) to €273.6 million, with high-value solutions.
Business Wire5/7/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on STVN and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 8/18/2026